Tetrahydroquinolinone derivatives as potent P-glycoprotein inhibitors: design, synthesis, biological evaluation and molecular docking analysisElectronic supplementary information (ESI) available: IR, MAS and NMR spectra. See DOI: 10.1039/c7md00178a

P-glycoprotein (P-gp) is a transmembrane efflux pump that has been associated with ineffective cancer chemotherapy and multidrug resistance (MDR). Chemical inhibitors of P-gp could have potential cancer therapeutic applications by preventing or reversing MDR. To exploit this, we designed twenty-five...

Full description

Saved in:
Bibliographic Details
Main Authors Ranjbar, S, Firuzi, O, Edraki, N, Shahraki, O, Saso, L, Khoshneviszadeh, M, Miri, R
Format Journal Article
LanguageEnglish
Published 18.10.2017
Online AccessGet full text

Cover

Loading…
Abstract P-glycoprotein (P-gp) is a transmembrane efflux pump that has been associated with ineffective cancer chemotherapy and multidrug resistance (MDR). Chemical inhibitors of P-gp could have potential cancer therapeutic applications by preventing or reversing MDR. To exploit this, we designed twenty-five tetrahydroquinolinone analogs bearing pyridyl methyl carboxylate at C 3 and different substituents at C 4 as MDR reversal agents. The inhibitory effects of the synthesized compounds against P-gp were assessed by flow cytometric determination of rhodamine 123 accumulation in P-gp over-expressing MES-SA/DX5 cells. Fluorescence imaging of intracellular rhodamine 123 accumulation in MES-SA/DX5 cells was also performed. Furthermore, the effect of active derivatives on the reduction of doxorubicin's IC 50 in MES-SA/DX5 cells was evaluated using MTT assay. Molecular docking was used to confirm the binding mode of some of the synthesized compounds. Five compounds in group A, bearing a 2-pyridyl methyl ester substituent at the C 3 position, significantly increased rhodamine accumulation at 25 μM comparable to verapamil, a well-established P-gp inhibitor, while only 2 compounds in group B bearing 3-pyridyl methyl ester at the same position had this effect. This study shows that tetrahydroquinolinones containing methyl pyridine esters could represent an attractive scaffold for the discovery of P-gp inhibitors as MDR reversal agents in cancer cells. Tetrahydroquinolinones bearing a phenyl ring with electron-withdrawing substitution showed remarkable P-glycoprotein inhibitory activity and significantly increased rhodamine accumulation in MES-SA/DX5 cells.
AbstractList P-glycoprotein (P-gp) is a transmembrane efflux pump that has been associated with ineffective cancer chemotherapy and multidrug resistance (MDR). Chemical inhibitors of P-gp could have potential cancer therapeutic applications by preventing or reversing MDR. To exploit this, we designed twenty-five tetrahydroquinolinone analogs bearing pyridyl methyl carboxylate at C 3 and different substituents at C 4 as MDR reversal agents. The inhibitory effects of the synthesized compounds against P-gp were assessed by flow cytometric determination of rhodamine 123 accumulation in P-gp over-expressing MES-SA/DX5 cells. Fluorescence imaging of intracellular rhodamine 123 accumulation in MES-SA/DX5 cells was also performed. Furthermore, the effect of active derivatives on the reduction of doxorubicin's IC 50 in MES-SA/DX5 cells was evaluated using MTT assay. Molecular docking was used to confirm the binding mode of some of the synthesized compounds. Five compounds in group A, bearing a 2-pyridyl methyl ester substituent at the C 3 position, significantly increased rhodamine accumulation at 25 μM comparable to verapamil, a well-established P-gp inhibitor, while only 2 compounds in group B bearing 3-pyridyl methyl ester at the same position had this effect. This study shows that tetrahydroquinolinones containing methyl pyridine esters could represent an attractive scaffold for the discovery of P-gp inhibitors as MDR reversal agents in cancer cells. Tetrahydroquinolinones bearing a phenyl ring with electron-withdrawing substitution showed remarkable P-glycoprotein inhibitory activity and significantly increased rhodamine accumulation in MES-SA/DX5 cells.
Author Firuzi, O
Edraki, N
Shahraki, O
Ranjbar, S
Khoshneviszadeh, M
Miri, R
Saso, L
AuthorAffiliation Zahedan University of Medical Sciences
School of Pharmacy
Department of Medicinal Chemistry
Shiraz University of Medical Sciences
Department of Physiology and Pharmacology "Vittorio Ersparmer"
Medicinal and Natural Products Chemistry Research Center
Sapienza University of Rome
AuthorAffiliation_xml – name: Department of Medicinal Chemistry
– name: Shiraz University of Medical Sciences
– name: Department of Physiology and Pharmacology "Vittorio Ersparmer"
– name: School of Pharmacy
– name: Medicinal and Natural Products Chemistry Research Center
– name: Sapienza University of Rome
– name: Zahedan University of Medical Sciences
Author_xml – sequence: 1
  givenname: S
  surname: Ranjbar
  fullname: Ranjbar, S
– sequence: 2
  givenname: O
  surname: Firuzi
  fullname: Firuzi, O
– sequence: 3
  givenname: N
  surname: Edraki
  fullname: Edraki, N
– sequence: 4
  givenname: O
  surname: Shahraki
  fullname: Shahraki, O
– sequence: 5
  givenname: L
  surname: Saso
  fullname: Saso, L
– sequence: 6
  givenname: M
  surname: Khoshneviszadeh
  fullname: Khoshneviszadeh, M
– sequence: 7
  givenname: R
  surname: Miri
  fullname: Miri, R
BookMark eNqFkE1PAjEQhhujiYhcvJuMN00AuyyGj5tRjBxQA9zJ0C3LaLetbXeT_eceLWr0YKJzmc_3eZM5YvvaaMnYScK7CU9Hl2JQZJwngyHusUaP93mnd5Uk-981Tw9Zy_tnHiPtDYejfoO9LWVwuK0zZ15L0kbRDgqZdFRhoEp6QA_WBKkDPHVyVQtjXWxJA-ktrSkY58dR4CnXbfC1DttY-zasySiTk0AFskJVRpzRgDqDwigpSoUOMiNeSOdxiqqOqklcBGc0CfCltUoW0RddHb02xhWfiPPJYnoBWCEpXCs5hum8DbPrxQf7YTYHb3cU7MJCSrh9nI7h94uO2cEGlZetr9xkp3eT5c19x3mxso6K6Lr6OU-b7Oyv_cpmm_Q_xjs4bYp0
ContentType Journal Article
DOI 10.1039/c7md00178a
DatabaseTitleList
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 2040-2511
EndPage 1933
ExternalDocumentID c7md00178a
GroupedDBID -JG
0-7
705
7~J
AAEMU
ABGFH
ACLDK
ADSRN
AEFDR
AFVBQ
AGSTE
AUDPV
BSQNT
C6K
EE0
EF-
H~N
J3I
RCNCU
RPMJG
RRC
RSCEA
SKF
SKH
SKJ
SKM
SKR
SKZ
SLC
SLF
SMJ
ID FETCH-rsc_primary_c7md00178a3
ISSN 2040-2503
IngestDate Mon Jan 28 17:14:44 EST 2019
Sun Jun 02 15:21:47 EDT 2019
IsPeerReviewed false
IsScholarly true
Issue 1
Language English
LinkModel OpenURL
MergedId FETCHMERGED-rsc_primary_c7md00178a3
Notes Electronic supplementary information (ESI) available: IR, MAS and NMR spectra. See DOI
10.1039/c7md00178a
PageCount 15
ParticipantIDs rsc_primary_c7md00178a
ProviderPackageCode J3I
ACLDK
RRC
7~J
SKZ
AEFDR
SLC
RCNCU
SLF
EE0
RSCEA
AFVBQ
C6K
H~N
0-7
RPMJG
-JG
AGSTE
AUDPV
EF-
BSQNT
SKF
SKH
SMJ
SKJ
SKM
ADSRN
ABGFH
SKR
705
AAEMU
PublicationCentury 2000
PublicationDate 20171018
PublicationDateYYYYMMDD 2017-10-18
PublicationDate_xml – month: 10
  year: 2017
  text: 20171018
  day: 18
PublicationDecade 2010
PublicationYear 2017
References_xml – issn: 2005
  publication-title: Principles of internal medicine
  doi: Hauser JAMERSON
– issn: 2016
  publication-title: World
  doi: Stewart Wild
SSID ssj0000328894
Score 4.28114
Snippet P-glycoprotein (P-gp) is a transmembrane efflux pump that has been associated with ineffective cancer chemotherapy and multidrug resistance (MDR). Chemical...
SourceID rsc
SourceType Enrichment Source
Publisher
StartPage 1919
Title Tetrahydroquinolinone derivatives as potent P-glycoprotein inhibitors: design, synthesis, biological evaluation and molecular docking analysisElectronic supplementary information (ESI) available: IR, MAS and NMR spectra. See DOI: 10.1039/c7md00178a
Volume 8
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3NT9swFMCtjl24TIOBBgz0DggNNWGl6UfaG4IiOqm0KkXiVjlxSoMgrZIUKfyt-0N25D27iVM1k7ZdospW0sTvp-dn-30wdsztitPwKq7pikbFpBnCbKEZb_JmzbPrE8e1Zfm23m3j5r7286H-UCr9ynktLWLnzH0rjCv5H6liG8qVomT_QbLZQ7EBf6N88YoSxuvfydiLUVckgrS7H1D5nVlAcVChLFlG-WR5VJ7PYjrvH5iPz4k7k3kZfHJvnPqOT6V2aE9ASD8OGu4oCdAkjFTmAZWhSYpRZwWXxw0vaVXdskCFqgIdVXaTjq6rE1HFUOWdHlJ4YRYoSWZt565LOxL8lfvPFL5Fr9GVXhm9izv5H7e9YVkGgob8DHWaV77qd-UGhozhpwSmbvNF0ARoZ3PLkAdPDl-tJXbth4s36bTQz9YPIuSqXrc-iZryadrYz--F4Px6rg6mU5VZJf9INOqUyvTybUuVvtT59hraSn_j6rWVswXQurUK55nCr1zN2607P7CPVVSDjdxekrQTrKpty0qd2Wun-XOt1g99O1o9YVqNRlo9o8_s03K5AheKvS1W8oJtdjJQ-c4TA0Y6fC8y4AQGOhN68oX9LgQUcoACj0ABCquAgga0DQpPAzI4DdBogkYTEBvI0IQlmrCOJqygCTk04TuCeQoZlm3oDg1AJOWzEUlIkQREEhDJNqwP5g47vO6MLm9MHNLxXCV0Getua5dt0Eh8ZSC4h0t7l1Y8To1cBs9xpTDhE6vFm8Kpiz22W_yMPbZf3DGei8n-n-46YJua6G9sIw4X3iHau7FzJLF5B9-ytzg
link.rule.ids 315,783,787,27936,27937
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tetrahydroquinolinone+derivatives+as+potent+P-glycoprotein+inhibitors%3A+design%2C+synthesis%2C+biological+evaluation+and+molecular+docking+analysisElectronic+supplementary+information+%28ESI%29+available%3A+IR%2C+MAS+and+NMR+spectra.+See+DOI%3A+10.1039%2Fc7md00178a&rft.au=Ranjbar%2C+S&rft.au=Firuzi%2C+O&rft.au=Edraki%2C+N&rft.au=Shahraki%2C+O&rft.date=2017-10-18&rft.issn=2040-2503&rft.eissn=2040-2511&rft.volume=8&rft.issue=1&rft.spage=1919&rft.epage=1933&rft_id=info:doi/10.1039%2Fc7md00178a&rft.externalDocID=c7md00178a
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2040-2503&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2040-2503&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2040-2503&client=summon